Spectral Medical Inc T.EDT

No More Equity Issues

[Accountprince]

I agree with Revten and MM about the buying opportunity.  So I have no problem with existing shareholders acquiring at low prices to combat the regular dilution that has occurred through bad equity raises.

Where I do have a problem is the apparent careless and thoughtless issue of equity spearheaded by our CFO/COO/CEO.  We've witnessed an issue at $0.60 per unit in 2020 that served to drag the trading price from around $0.80 per share into the $0.55 range.  Poor planning or poor execution or both.  Then this year an apparent spur of the moment issue at $0.425 per unit when we were trading in the mid to upper $0.55 per share range.  Continuing poor planning or poor execution or both.

My biggest fear is the bumbling will continue while we're in the $0.21 per share range.  Will an idiotic issue be done at say $0.15 per unit?  We should insist that a proper marketing be done now with assurances no more share issues will be done until it bears fruit.  Indeed we could even set a floor price of returning to the $0.80 per share level we had before the bumbling started.  Then issues can be done at that level or better.  If we need real IR and promotion in Canada and the US then get some.  We have been spending valuable dollars (raised at stupidly low share prices) to pay these people overseeing the program.  Time for us to get real value for dollars spent including the C suite.

[BayStreetWild]

time to sell dialco. If they got enough for it to finish our main trial I would be happy.   

[Accountprince]

BS Wild - your solution is worse than the continuing bumbling that has occurred and in the absence of change likely will continue to occur.  The suggestion I made was to set parameters for those drawing valuable dollars from our company.  I suggested a floor threshold for future equity issues be set at the modest level our share price had achieved before their bumbling commenced. 

[hmmmmmmmm]

PR and IR work when you're selling sizzle. They aren't going to stick their necks out any farther while trying to please the FDA. They just need to deliver on the trial enrollements and the rest will come. If you look back to 2016 the price ran from .74 to 1.80 over 5 mos as the trial was winding down. A DIMI/ DaVita trial partnership would be a sweet signal/ kick in the asss too.

[mercedesman]

They have the steaks !  Two very nice ones at that! And they could generate plenty of sizzle if they really wanted to. Conservatism, and fear of upsetting the FDA appears to be ruling the day.  If that is the case then I totally agree with AP - stop with the the ridiculous and irresponsbible capital raises, until you CAN or WILL sell the sizzle! "Keep away" is a frustrating

[Domino55]

Sizzle? This hasn't sizzled since the Fall of 2016 when they brought that to an end with the erroneous and highly broadcast news of a trial failure. Curiously, but really not surprisingly we are now trading below the October 2016 levels. There is a lot of advancements here being sold as worthless at 20 cents/share.

[mercedesman]

Right you are  I remember buying some in the twenties back then. Unless you were fleet of foot, it was hard to bottom fish. Back then the DIMI was but a twinkle in it's parents eyes. And they know so much more about the PMX now (where, and when & how it works) 100,000+ additional safe uses since then as well (mainly Japan and Italy, but in many other countries as well. Then of

[Domino55]

I don't know much about the bead people but they have accomplished a lot with their SP considering they are nowhere with the FDA. On the flip side of the accomplishment globe is Spectral. 400 was enough to wipe out 14% of market EDTXF market cap today. They try so hard but just can't get any US traction. Man they sure do struggle down there. Maybe that whole Sepsis thing is a passing fad

[Domino55]

AP: I don't think they would attempt to raise at 15 cents although that is the next support level. Then again why not!